Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

• Status: Terminated
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Geisinger Clinic
• Collaborator: Genentech, Inc.
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Stage III, IV SCCHN

• Completed curative treatment

Exclusion Criteria:

• Prior chemotherapy or radiotherapy

• Recurrent disease